Company: NDRA
Filing Date: 2025-04-02
Form Type: S-8
Source: 0001654954-25-003848
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-04-02
Form: S-8
Chunk 0
---
<div align='center'>As filed with the Securities and Exchange Commission on April 2, 2025</div>

Registration No. 333-

<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</div>

| ENDRA LIFE SCIENCES INC.                               |
| (Exact name of registrant as specified in its charter) |

| Delaware                                                       |     |                          26-0579295 |
| (State or other jurisdiction of incorporation or organization) |     | -I.R.S. Employer Identification No. |
| 3600 Green Court, Suite 350 Ann Arbor, MI                      |     |                               48105 |
| (Address of principal executive offices)                       |     |                           -Zip Code |

<div align='center'>ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan

(Full title of the plan)

Alexander Tokman

Acting Chief Executive Officer

ENDRA Life Sciences Inc.

3600 Green Court, Suite 350

Ann Arbor, MI 48105

(Name and address of agent for service)

(734) 335-0468

(Telephone number, including area code,

of agent for service)</div>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer | ☐ | Accelerated filer         | ☐ |
| Non-accelerated filer   | ☒ | Smaller reporting company | ☒ |
|                         |   | Emerging growth company   | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<div align='center'>EXPLANATORY NOTE</div>

This Registration Statement on Form S-8 is being filed to register an additional 178,033 shares of Common Stock under the ENDRA Life Sciences Inc. 2016 Omnibus